Wu Zhiping,Zou Yun,Fu Ronghua,et al.Current status of diagnosing and treating fibro-adipose vascular anomaly[J].Journal of Clinical Pediatric Surgery,2023,22(08):796-800.[doi:10.3760/cma.j.cn101785-202210019-019]
法瓦病的诊疗现状
- Title:
- Current status of diagnosing and treating fibro-adipose vascular anomaly
- Keywords:
- Fibro-Adipose Vascular Anomaly; Vascular Malformations; Diagnosis; Differential; Therapy; Treatment Outcome
- 摘要:
- 法瓦病（fibro-adipose vascular anomaly，FAVA）是一种复杂的良性脉管类疾病，多见于儿童和青少年，主要临床表现为受累肢体的持续性疼痛和痉挛。由于既往对FAVA的认识不足，造成临床医师对该病的诊治存在较多困惑。为进一步提高临床医师对FAVA的认识，本文对FAVA的发病机制、临床表现、影像学特征及治疗进展进行综述，为FAVA的临床诊治提供参考。
- Abstract:
- As a complex benign vascular disease, fibro-adipose vascular anomaly (FAVA) consists of intramuscular vascular malformation, fibrous tissue and adipose tissue.It is more prevalent among children and adolescents.Its clinical manifestations are persistent pain and contracture in affected extremity.Due to a previous lack of its etiological mechanism, there is a lot of confusion in the diagnosis and treatment of this disease.For further enhancing clinicians’ understanding of FAVA, this review focused upon its pathogenesis, clinical manifestations, imaging features and therapeutic advances for optimizing its clinical managements.
参考文献/References:
[1] Alomari AI, Spencer SA, Arnold RW, et al.Fibro-adipose vascular anomaly:clinical-radiologic-pathologic features of a newly delineated disorder of the extremity[J].J Pediatr Orthop, 2014, 34(1):109-117.DOI:10.1097/BPO.0b013e3182a1f0b8.
[2] Fernandez-Pineda I, Marcilla D, Downey-Carmona FJ, et al.Lower extremity fibro-adipose vascular anomaly (FAVA):a new case of a newly delineated disorder[J].Ann Vasc Dis, 2014, 7(3):316-319.DOI:10.3400/avd.cr.14-00049.
[3] 刘大看, 龚毓宾, 左松, 等.34例下肢法瓦病临床分析[J].中华整形外科杂志, 2017, 33(6):433-437.DOI:10.3760/cma.j.issn.1009-4598.2017.06.008. Liu DK, Gong YB, Zuo S, et al.Retrospective clinical analysis of 34 cases with fibro-adipose vascular anomaly on lower extremities[J].Chin J Plast Surg, 2017, 33(6):433-437.DOI:10.3760/cma.j.issn.1009-4598.2017.06.008.
[4] Amarneh M, Shaikh R.Clinical and imaging features in fibro-adipose vascular anomaly (FAVA)[J].Pediatr Radiol, 2020, 50(3):380-387.DOI:10.1007/s00247-019-04571-6.
[5] Luks VL, Kamitaki N, Vivero MP, et al.Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA[J].J Pediatr, 2015, 166(4):1048-1054.e5.DOI:10.1016/j.jpeds.2014.12.069.
[6] Hori Y, Hirose K, Aramaki-Hattori N, et al.Fibro-adipose vascular anomaly (FAVA):three case reports with an emphasis on the mammalian target of rapamycin (mTOR) pathway[J].Diagn Pathol, 2020, 15(1):98.DOI:10.1186/s13000-020-01004-z.
[7] Hori Y, Hirose K, Ozeki M, et al.PIK3CA mutation correlates with mTOR pathway expression but not clinical and pathological features in Fibfibroipose vascular anomaly (FAVA)[J].Diagn Pathol, 2022, 17(1):19.DOI:10.1186/s13000-022-01199-3.
[8] Driskill JH, Hwang H, Callan AK, et al.Case report of fibro-adipose vascular anomaly (FAVA) with activating somatic PIK3CA mutation[J].Case Rep Genet, 2022, 2022:9016497.DOI:10.1155/2022/9016497.
[9] Castillo SD, Baselga E, Graupera M.PIK3CA mutations in vascular malformations[J].Curr Opin Hematol, 2019, 26(3):170-178.DOI:10.1097/MOH.0000000000000496.
[10] Blesinger H, Kaulfuβ S, Aung T, et al.PIK3CA mutations are specifically localized to lymphatic endothelial cells of lymphatic malformations[J].PLoS One, 2018, 13(7):e0200343.DOI:10.1371/journal.pone.0200343.
[11] Castel P, Carmona FJ, Grego-Bessa J, et al.Somatic PIK3CA mutations as a driver of sporadic venous malformations[J].Sci Transl Med, 2016, 8(332):332ra42.DOI:10.1126/scitranslmed.aaf1164.
[12] Whalen SG, Gingras AC, Amankwa L, et al.Phosphorylation of eIF-4E on serine 209 by protein kinase C is inhibited by the translational repressors, 4E-binding proteins[J].J Biol Chem, 1996, 271(20):11831-11837.DOI:10.1074/jbc.271.20.11831.
[13] Dennis PB, Pullen N, Kozma SC, et al.The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases[J].Mol Cell Biol, 1996, 16(11):6242-6251.DOI:10.1128/MCB.16.11.6242.
[14] Uller W, Fishman SJ, Alomari AI.Overgrowth syndromes with complex vascular anomalies[J].Semin Pediatr Surg, 2014, 23(4):208-215.DOI:10.1053/j.sempedsurg.2014.06.013.
[15] Klemme WR, James P, Skinner SR.Latent onset unilateral toe-walking secondary to hemangioma of the gastrocnemius[J].J Pediatr Orthop, 1994, 14(6):773-775.DOI:10.1097/01241398-199414060-00016.
[16] Umehara F, Matsuura E, Kitajima S, et al.Unilateral toe-walking secondary to intramuscular hemangioma in the gastrocnemius[J].Neurology, 2005, 65(7):E15.DOI:10.1212/01.wnl.0000175077.49389.7d.
[17] Sutherland AD.Equinus deformity due to haemangioma of calf muscle[J].J Bone Joint Surg Br, 1975, 57(1):104-105.
[18] 胡文笳, 刘昱晗, 董长宪, 等.下肢法瓦病与静脉畸形的超声影像学特征解析[J].中华整形外科杂志, 2022, 38(3):259-264.DOI:10.3760/cma.j.cn114453-20210703-00282. Hu WJ, Liu YH, Dong CX, et al.Application of ultrasound for differentiating lower extremities fibro-adipose vascular anomaly and venous malformations[J].Chin J Plast Surg, 2022, 38(3):259-264.DOI:10.3760/cma.j.cn114453-20210703-00282.
[19] Hu WJ, Gong YB, Ma JJ, et al.Fibro-adipose vascular anomaly:characteristic imaging features on sonography and magnetic resonance imaging[J].Vasc Endovascular Surg, 2023, 57(2):106-113.DOI:10.1177/15385744221129973.
[20] Khera PS, Garg PK, Babu S, et al.Fibro adipose vascular anomaly:a rare and often misdiagnosed entity[J].Indian J Radiol Imaging, 2021, 31(3):776-781.DOI:10.1055/s-0041-1736399.
[21] 付芳芳, 董健, 刘秋雨, 等.肌内法瓦病的MRI表现及病理对照分析[J].中华放射学杂志, 2022, 56(8):868-872.DOI:10.3760/cma.j.cn112149-20210810-00740. Fu FF, Dong J, Liu QY, et al.MRI findings and pathological analysis of intramuscular fibro-adipose vascular anomaly[J].Chin J Radiol, 2022, 56(8):868-872.DOI:10.3760/cma.j.cn112149-20210810-00740.
[22] Ferreira J, López Gutiérrez JC, Carneiro A, et al.Lower extremity fibro-adipose vascular anomaly-case report[J].Ann Vasc Surg, 2020, 66:671.e15-671.e18.DOI:10.1016/j.avsg.2020.01.089.
[23] Cheung K, Taghinia AH, Sood RF, et al.Fibroadipose vascular anomaly in the upper extremity:a distinct entity with characteristic clinical, radiological, and histopathological findings[J].J Hand Surg Am, 2020, 45(1):68.e1-68.e13.DOI:10.1016/j.jhsa.2019.05.008.
[24] Hein KD, Mulliken JB, Kozakewich HPW, et al.Venous malformations of skeletal muscle[J].Plast Reconstr Surg, 2002, 110(7):1625-1635.DOI:10.1097/01.PRS.0000033021.60657.74.
[25] Johnson CM, Navarro OM.Clinical and sonographic features of pediatric soft-tissue vascular anomalies part 2:vascular malformations[J].Pediatr Radiol, 2017, 47(9):1196-1208.DOI:10.1007/s00247-017-3906-x.
[26] Ernemann U, Kramer U, Miller S, et al.Current concepts in the classification, diagnosis and treatment of vascular anomalies[J].Eur J Radiol, 2010, 75(1):2-11.DOI:10.1016/j.ejrad.2010.04.009.
[27] 代诗懿, 彭素华, 陈思源, 等.卡波西样血管内皮瘤的研究进展[J].临床小儿外科杂志, 2020, 19(6):544-547, 553.DOI:10.3969/j.issn.1671-6353.2020.06.016. Dai SY, Peng SH, Chen SY, et al.Recent advances in researches and treatments of Kaposiform hemangioendothelioma[J].J Clin Ped Sur, 2020, 19(6):544-547, 553.DOI:10.3969/j.issn.1671-6353.2020.06.016.
[28] 吴志平, 邹筠, 傅荣华, 等.小儿卡波西型血管内皮瘤的个体化治疗分析[J].中华普通外科学文献(电子版), 2022, 16(5):354-359.DOI:10.3877/cma.j.issn.1674-0793.2022.05.009. Wu ZP, Zou J, Fu RH, et al.Analysis of individualized treatment of Kaposiform hemangioendothelioma in infants[J].Chin Arch Gen Surg (Electronic Edition), 2022, 16(5):354-359.DOI:10.3877/cma.j.issn.1674-0793.2022.05.009.
[29] Wang SK, Drucker NA, Gupta AK, et al.Diagnosis and management of the venous malformations of Klippel-Trénaunay syndrome[J].J Vasc Surg Venous Lymphat Disord, 2017, 5(4):587-595.DOI:10.1016/j.jvsv.2016.10.084.
[30] Harna B, Tomar S.Klippel trenaunay syndrome[J].Indian J Pediatr, 2020, 87(11):966-967.DOI:10.1007/s12098-019-03178-x.
[31] Abdel Razek AAK.Imaging findings of Klippel-Trenaunay syndrome[J].J Comput Assist Tomogr, 2019, 43(5):786-792.DOI:10.1097/RCT.0000000000000895.
[32] Dubois J, Garel L.Imaging and therapeutic approach of hemangiomas and vascular malformations in the pediatric age group[J].Pediatr Radiol, 1999, 29(12):879-893.DOI:10.1007/s002470050718.
[33] Dubois J, Alison M.Vascular anomalies:what a radiologist needs to know[J].Pediatr Radiol, 2010, 40(6):895-905.DOI:10.1007/s00247-010-1621-y.
[34] Hussein A, Malguria N.Imaging of vascular malformations[J].Radiol Clin North Am, 2020, 58(4):815-830.DOI:10.1016/j.rcl.2020.02.003.
[35] Lipede C, Nikkhah D, Ashton R, et al.Management of fibro-adipose vascular anomalies (FAVA) in paediatric practice[J].JPRAS Open, 2021, 29:71-81.DOI:10.1016/j.jpra.2021.05.002.
[36] Bagga B, Goyal A, Das A, et al.Clinicoradiologic predictors of sclerotherapy response in low-flow vascular malformations[J].J Vasc Surg Venous Lymphat Disord, 2021, 9(1):209-219.e2.DOI:10.1016/j.jvsv.2020.03.011.
[37] Cao JJ, Liu JJ, Zhang XY, et al.A systematic review and network meta-analysis of the effectiveness of sclerotherapy for venous malformation[J].J Vasc Surg Venous Lymphat Disord, 2023, 11(1):210-218.e3.DOI:10.1016/j.jvsv.2022.08.004.
[38] 林向上, 邓立才, 姚佳星, 等.淋巴管畸形介入硬化治疗的效果分析[J].临床小儿外科杂志, 2020, 19(6):518-522.DOI:10.3969/j.issn.1671-6353.2020.06.011. Lin XS, Deng LC, Yao JX, et al.Clinical efficacies of interventional sclerotherapy for lymphatic malformation[J].J Clin Ped Sur, 2020, 19(6):518-522.DOI:10.3969/j.issn.1671-6353.2020.06.011.
[39] Clemens RK, Pfammatter T, Meier TO, et al.Combined and complex vascular malformations[J].Vasa, 2015, 44(2):92-105.DOI:10.1024/0301-1526/a000414.
[40] Kwak K, Yu B, Lewandowski RJ, et al.Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation[J].Theranostics, 2022, 12(5):2175-2204.DOI:10.7150/thno.67530.
[41] Shaikh R, Alomari AI, Kerr CL, et al.Cryoablation in fibro-adipose vascular anomaly (FAVA):a minimally invasive treatment option[J].Pediatr Radiol, 2016, 46(8):1179-1186.DOI:10.1007/s00247-016-3576-0.
[42] Ramaswamy RS, Tiwari T, Darcy MD, et al.Cryoablation of low-flow vascular malformations[J].Diagn Interv Radiol, 2019, 25(3):225-230.DOI:10.5152/dir.2019.18278.
[43] 谢崇, 王怀杰, 蔺卫龙, 等.法瓦病诊疗方法的初步探索[J].中华小儿外科杂志, 2022, 43(2):146-150.DOI:10.3760/cma.j.cn421158-20201030-00682. Xie C, Wang HJ, Lin WL, et al.Preliminary exploration of diagnosing and treating fibroadipose vascular anomaly[J].Chin J Pediatr Surg, 2022, 43(2):146-150.DOI:10.3760/cma.j.cn421158-20201030-00682.
[44] Wang KK, Glenn RL, Adams DM, et al.Surgical management of fibroadipose vascular anomaly of the lower extremities[J].J Pediatr Orthop, 2020, 40(3):e227-e236.DOI:10.1097/BPO.0000000000001406.
[45] Lackner H, Karastaneva A, Schwinger W, et al.Sirolimus for the treatment of children with various complicated vascular anomalies[J].Eur J Pediatr, 2015, 174(12):1579-1584.DOI:10.1007/s00431-015-2572-y.
[46] Adams DM, Trenor CC 3rd, Hammill AM, et al.Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies[J].Pediatrics, 2016, 137(2):e20153257.DOI:10.1542/peds.2015-3257.
[47] Heberle AM, Rehbein U, Rodríguez Peiris M, et al.Finding new edges:systems approaches to MTOR signaling[J].Biochem Soc Trans, 2021, 49(1):41-54.DOI:10.1042/BST20190730.
相似文献/References:
[1]王怀杰,谢崇,蔺卫龙,等.纤维脂肪血管病变13例的诊断与治疗[J].临床小儿外科杂志,2022,21(07):668.[doi:10.3760/cma.j.cn101785-202102022-014]
Wang Huaijie,Xie Chong,Lin Weilong,et al.Diagnosis and treatment of fibro-adipose vascular anomaly(FAVA)[J].Journal of Clinical Pediatric Surgery,2022,21(08):668.[doi:10.3760/cma.j.cn101785-202102022-014]
备注/Memo
收稿日期:2022-10-12。
通讯作者:袁华,Email:nizhongboc@163.com